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Background: Ocular signs of Fabry disease can be seen in the first decade of life.
Methods: We examined the occurrence of ocular signs in 232 paediatric patients in the Fabry Outcome Survey
(FOS) international registry and looked for relationships between the presence of eye findings and disease severity
as measured by the FOS Mainz severity score index (FOS-MSSI).
Results: At least one ocular sign was found in 55/101 (54.5%) girls and 62/131 (47.3%) boys: cornea verticillata in
53/101 (52.5%) girls and 55/131 (42.0%) boys, vessel tortuosity in 17/98 (17.3%) girls and 32/131 (24.4%) boys, and
posterior spoke-like lens opacities in 3/97 (3.1%) girls and 2/130 (1.5%) boys. Summary statistics showed higher
median (range) age-adjusted FOS-MSSI total score indicating more severe disease in children with eye findings
versus those without eye findings (0.5 [−11.0, 20.7] versus −2.3 [−11.1, 18.8]). At least one eye finding was observed
in 59.1% of treated and 37.9% of untreated children.
Conclusions: We conclude that the presence of ocular signs, particularly cornea verticillata, correlates with more
severe disease as indicated by FOS-MSSI scores in paediatric patients with Fabry disease. Ocular signs appear in
roughly half of school-aged children with Fabry disease and are well-recognised as a valuable tool for diagnosis of
Fabry disease in children; they also may help identify patients who are at risk for developing early severe
manifestations of Fabry disease and who should be further evaluated and closely followed up.
Keywords: Agalsidase alfa, Children, Fabry disease, Fabry Outcome Survey, Ocular signsBackground
Fabry disease (OMIM number 301500) is a genetic
disorder that typically causes reduced life expectancy in
males and even in heterozygous females [1–4]. Functional
insufficiency of the lysosomal enzyme α-galactosidase A
(Enzyme Commission number 3.2.1.22) leads to progres-
sive accumulation of glycosphingolipids in many tissues,
with associated morbidity and mortality [3]. Early diagno-
sis is important to monitor disease progression; further,
timely initiation of enzyme replacement therapy (ERT)
before irreversible end organ damage occurs, along with* Correspondence: g.kalkum@web.de
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may improve patient outcomes [5].
Fabry disease can manifest in childhood [6–9]. As in
adults [10, 11], these include acute and chronic neuro-
pathic pain, hypohidrosis, angiokeratoma, gastrointestinal
symptoms, and reduced quality of life [6–8, 12, 13]. Fabry
disease is also associated with ocular signs, which typically
do not impair vision and have been reported to occur as
early as the first decade of life [14, 15]; corneal findings
have even been described in a 22-week foetus [16].
Characteristic ocular signs of Fabry disease fall into three
categories: corneal changes, vascular changes, and posterior
spoke-like lens opacities [15, 17, 18]. The cornea may
exhibit linear deposits called cornea verticillata (CV) and/or
a diffuse corneal haze. Vascular changes in Fabry disease
include increased tortuosity of conjunctival and/orle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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vessels. Further, a recent report of 38 individuals with
Fabry disease described the presence of vascular tor-
tuosity in 36 (94.7%) and microaneurysms in 10
(26.3%) patients on the external surface of the super-
ior eyelid [19]. Conjunctival aneurysms are associated
with glycosphingolipid deposits within endothelial
cells, smooth muscle cells of the media, and in the
surrounding connective tissue, which are believed to
compromise vessel wall stability and enable formation
of irregular dilations of the vessels [20, 21]. Lens
opacities include a spoke-like opacity of the posterior
lens capsule, referred to as a “Fabry cataract”; anterior
lens deposits also can occur [17].
Although conjunctival aneurysms are not described in
other chronic illnesses, CV and tortuosity of retinal and
conjunctival vessels are not limited to Fabry disease.
Increased ocular vessel tortuosity has also been reported in
patients with fucosidosis [22, 23] and GM1 gangliosidosis
[24, 25]; treatment with amphiphilic drugs such as amioda-
rone, chloroquine, hydroxychloroquine, and indomethacin
may be associated with drug-induced symmetric corneal
changes that have some similarities to those seen in Fabry
disease [26–28]; and lens opacities similar to Fabry cataract
have been described in patients with mannosidosis and
other lysosomal storage disorders [29].
The Fabry Outcome Survey (FOS) is an international
registry sponsored by Shire for all patients with Fabry
disease who are receiving or are candidates for ERT with
agalsidase alfa. The FOS database provides information
on a worldwide population of patients. A recent analysis
of data from 1203 adult patients in FOS showed that
patients with eye signs such as CV had more severe dis-
ease than patients without any eye signs, demonstrating
a correlation between ocular manifestations of Fabry
disease and disease severity [30]. The current analysis
objective was to examine any correlations between eye
findings and disease severity in paediatric patients in the
FOS database.
Methods
Patients and study design
FOS is an ongoing, prospective, observational registry
designed to collect clinical outcomes in patients with
Fabry disease who are treatment naïve, currently treated
with agalsidase alfa, or were previously treated with any
ERT. For this retrospective cross-sectional analysis, data
in FOS were collected from patients examined from
2001 through August 2014, with the approval of the
ethical review board at each participating centre (see list
in Additional file 1: Table S1). Upon enrolment into
FOS, written informed consent was obtained from each
patient (or parent/legal guardian for minor patients) and
a physician documented each patient’s medical history,the year of diagnosis, signs and symptoms of the
disease, and treatment. Depersonalised data were se-
lected for boys (hemizygotes) and girls (heterozygotes)
who underwent a detailed ocular examination, includ-
ing slit-lamp examination of the anterior segment, as
well as fundoscopy. The prevalence of Fabry-specific
eye abnormalities was analysed in the overall FOS
population, as previously described [30]. Ocular vessel
tortuosity was assessed semi-quantitatively (as none,
mild, moderate, or severe) by the examining eye care
practitioner and was not separated between retinal
and conjunctival vessels in the FOS database. FOS
collects real-world data on routine clinical evaluation
parameters. Therefore, no specific training was pro-
vided to practitioners to assure constancy and reliabil-
ity of data collection in this multicentre study. The
presence or absence of corneal haze and subepithelial
corneal lines was not reported as a sign and/or symp-
tom of Fabry disease in FOS.Statistical analyses
Descriptive summary statistics are presented. For categor-
ical parameters, numbers and percentages of affected
patients are reported; for continuous parameters, me-
dians and ranges are shown. The Wilcoxon nonpara-
metric statistic was used to compare groups. Statistical
analyses were conducted using SAS V.9.2 (SAS Institute
Inc., Cary, NC, USA), and data collection and analysis
were supported by Shire.
Associations between eye abnormalities and severity of
systemic involvement were evaluated using the disease-
specific FOS Mainz severity score index (FOS-MSSI)
[31, 32], which consists of four sections that cover
general, neurological, cardiovascular, and renal signs and
symptoms of Fabry disease [32]. Each section is weighted
according to its contribution to disease morbidity, and
individual organ-related scores are added to calculate
the total FOS-MSSI score, which is categorised as mild
(≤18), moderate (19–38), or severe (>38) [32]. Because
the FOS-MSSI scoring system was not developed for
and has not been validated in children, an age
adjustment of the FOS-MSSI score was calculated, using
an equation based on age [33, 34]. The age-adjusted
FOS-MSSI disease severity scores represent the observed
FOS-MSSI score minus the expected FOS-MSSI score
for that patient’s age; thus, a positive age-adjusted score
indicates the patient has more severe manifestations
than average, and a negative age-adjusted score indicates
the patient has less severe disease than average [33]. The
CV subscore was removed from the total FOS-MSSI
score to avoid skewing comparisons between patients
with and without CV. Ocular signs were correlated with
age-adjusted FOS-MSSI values.
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Baseline demographic and clinical characteristics
Among 2379 patients with data available at the August
3, 2014 extraction date, 255 were children at FOS entry;
232 underwent their first ocular examination before the
age of 18 years (Table 1). At least one of the eye findings
described was found in 117/232 (50.4%) children.
Observed eye findings included CV (Fig. 1a) in 108/232
(46.6%), retinal and/or conjunctival vessel tortuosity
(Fig. 1b, c) in 49/229 (21.4%), and posterior spoke-like
lens opacity (Fig. 1d) in 5/227 (2.2%) patients. More than
half (137/232; 59.1%) of the children received agalsidase
alfa treatment at any time.
Occurrence of eye findings by gender and age
Ocular signs of Fabry disease were noted in 55/101
(54.5%) girls and 62/131 (47.3%) boys who had under-
gone ocular examination (Table 1). CV was more com-
mon and tended to be seen at younger ages in girls than
boys (seen in 52.5% of girls and 42.0% of boys; median
age at first presentation, 8.9 years and 10.7 years, re-
spectively). This is consistent with previously published
reports [2, 3]. However, tortuous ocular vessels were
more common and tended to be seen at younger ages in
boys than girls (seen in 24.4% of boys and 17.3% of girls;
median age at first finding, 10.1 years in boys and
12.0 years in girls) and reflect more severe disease; this
was also seen in a previously published single-centre
study [35]. Posterior spoke-like lens opacities were un-
common, being reported in only three girls and two
boys.
Of the 232 children with ocular examinations, 108
patients had a first diagnosis of CV during the study
period. The distribution of first onset of CV by age
category is shown in Fig. 2.Table 1 Patient demographics and clinical characteristics
Variable
All FOS paediatric patients with ocular exam, n (%)
Children with any eye finding, n (%)
Children with CV, n (%)
Children with tortuous vesselsa, n (%)
Children with posterior spoke-like lens opacity, n (%)
Age of patients at first eye finding, years, median (range)
Agalsidase alfa treatment, n (%)
No
Yes (any time)
Patients with agalsidase alfa treatment and any eye finding
Patients with agalsidase alfa treatment and no eye findings
FOS Fabry Outcome Survey; CV cornea verticillata
aIncludes both retinal and conjunctival vessel tortuosityAmong the 19 children who had their last FOS-MSSI
assessments before 6 years of age, four (two females)
had eye findings; CV was seen in all four, tortuous
vessels in two girls, and none had lens opacities. Three
of the four children <6 years of age with eye findings
were symptomatic with neurological signs (including
hypohidrosis and/or anhidrosis). Of the 15/19 children
<6 years of age with no eye findings, two were treated
and six (four girls and two boys) had neurological symp-
toms of Fabry disease documented in FOS.
Occurrence of eye findings by agalsidase alfa treatment
status
Eighty one (59.1%) of the 137 treated paediatric patients
in this study had at least one eye finding, whereas 36
(37.9%) of the 95 untreated children had any eye findings.
Among the 41 treated girls, 27 (65.9%) had any eye
findings versus 14 (34.1%) without eye findings (Table 1).
Of the 117 children who had eye findings, 36 (30.8%)
had not received ERT during the study period, 61
(52.1%) had their first eye finding before starting ther-
apy, and 20 (17.1%) had their first eye finding after start-
ing therapy.
Occurrence of eye findings by Fabry disease severity
Summary statistics for any ocular sign (including CV,
tortuous retinal and/or conjunctival vessels, and poster-
ior spoke-like lens opacity) generally showed more
severe disease as measured by age-adjusted FOS-MSSI
total scores in children with eye findings versus those
without eye findings (median, 0.5 versus −2.3; p < 0.001;
Table 2). These differences were statistically significant
for the presence of any eye finding as well as for pres-
ence of CV and tortuous vessels (Table 2) and remained
consistent when boys and girls were grouped separately.Patients
Boys Girls Total
131 (56.5) 101 (43.5) 232 (100)
62/131 (47.3) 55/101 (54.5) 117/232 (50.4)
55/131 (42.0) 53/101 (52.5) 108/232 (46.6)
32/131 (24.4) 17/98 (17.3) 49/229 (21.4)
2/130 (1.5) 3/97 (3.1) 5/227 (2.2)
10.3 (2.3, 17.7) 8.9 (3.2, 16.4) 9.7 (2.3, 17.7)
35 (26.7) 60 (59.4) 95 (40.9)
96 (73.3) 41 (40.6) 137 (59.1)
54 (56.3) 27 (65.9) 81 (59.1)
42 (43.7) 14 (34.1) 56 (40.9)
Fig. 1 Typical ocular changes seen in Fabry disease. a Cornea verticillata. b Increased vessel tortuosity and aneurysms (arrows) in the temporal
bulbar conjunctiva. c Increased tortuosity of arteria/vena temporalis superior. d Lens opacity: faint spoke-like lines at the posterior lens capsule
Fig. 2 Distribution of patients by age category at first onset of cornea verticillata
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Table 2 Age-adjusted FOS-MSSI total score and eye changes
Age-adjusted FOS-MSSI total score (removing CV), median (range)
With eye findings Without eye findings p-value
All patients with assessment before 18 y (n = 232)
Any eye finding 0.5 (−11.0, 20.7), n = 117 −2.3 (−11.1, 18.8), n = 114 <0.001
CV 0.4 (−11.0, 20.7), n = 108 −2.2 (−11.1, 18.8), n = 123 <0.001
Tortuous vessels 3.3 (−8.7, 20.7), n = 49 −2.0 (−11.1, 20.5), n = 179 <0.001
Posterior spoke-like lens opacity 2.4 (−6.9, 20.5), n = 5 −1.3 (−11.1, 20.7), n = 221 0.257
Girls (n = 101)
Any eye finding 0.9 (−9.7, 21.8), n = 55 −2.7 (−9.6, 9.4), n = 46 0.002
CV 0.9 (−9.7, 21.8), n = 53 −2.7 (−9.6, 9.4), n = 48 0.002
Tortuous vessels 2.2 (−4.6, 21.8), n = 17 −1.8 (−9.7, 19.3), n = 81 0.003
Posterior spoke-like lens opacity 1.1 (−5.9, 5.5), n = 3 −0.7 (−9.7, 21.8), n = 94 0.763
Boys (n = 130)
Any eye finding 1.5 (−11.8, 19.8), n = 62 −2.8 (−11.9, 18.0), n = 68 <0.001
CV 0.3 (−11.8, 19.8), n = 55 −2.7 (−11.9, 18.0), n = 75 0.006
Tortuous vessels 3.6 (−9.4, 19.1), n = 32 −2.4 (−11.9, 19.8), n = 98 <0.001
Posterior spoke-like lens opacity 10.7 (1.7, 19.8), n = 2 −1.5 (−11.9, 19.1), n = 127 0.092
CV cornea verticillata, FOS-MSSI Fabry Outcome Survey Mainz severity score index
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assessment by the presence (or absence) of any eye lesion is
illustrated in a scatter plot (Additional file 2: Figure S1).
Children with eye findings (in red) had more severe disease
across all ages than children without any eye findings (in
black). Disease severity increased with age in children with
and without eye findings. As expected, disease severity
increased with age in each group (“any eye finding” and “no
eye finding”), and the differences between the two groups
remained quite constant over time; the “any eye finding”
group showed greater disease severity over all ages.
Discussion
This large study on the ocular manifestations of Fabry
disease confirms their presence even in some children
<6 years of age and points at a prevalence of ocular
involvement similar to that in the adult population. We there-
fore conclude that ocular examination is a valuable tool in
children with Fabry disease and ocular signs may be import-
ant for further monitoring, since children with ocular chan-
ges—similar to adults with Fabry disease—show more severe
disease burden. Slit-lamp examination should be routinely
used whenever possible in all patients with Fabry disease.
CV is the most common ocular sign in classical Fabry
disease, with a prevalence of approximately 50% among
adults in FOS [30]. The reported prevalence among all ages
(range, 3–71 years) in an earlier FOS study was higher,
ranging from 73.1% in male patients to 76.9% in female pa-
tients [36]. Likewise, a recent systematic review of 21 pub-
lished cohorts found a pooled prevalence of CV of 69%
among 753 patients ranging in age from 0 to 85 years [15].Interestingly, the prevalence of CV reported by van der Tol
et al [15] was markedly lower (around 24%) when only look-
ing at patients with non-classical Fabry disease phenotype.
Allen et al reported similar findings in that patients with the
cardiac variant had fewer ocular signs [35]. Previous reports
indicate a similar prevalence of CV in female and male pa-
tients of all ages [18, 30], and have suggested that ocular in-
volvement may be an indicator of disease severity. In an
analysis of ocular manifestations of Fabry disease in 173
adult patients included in FOS, a correlation was observed
between tortuous ocular vessels, higher FOS-MSSI values,
and impaired renal and cardiac function [36]. A recent ana-
lysis of data from 1203 adult patients in FOS showed that
patients with CV had more severe disease than patients
without any eye signs [30]. The overall prevalence of CV in
the current analysis was 46.6%, with a higher prevalence in
girls (52.5%) than boys (42.0%). These findings are consist-
ent with previous reports [6, 35].
Retinal and/or conjunctival vessel tortuosity was
observed in 21.4% of this cohort. Similarly, Allen et al
reported ocular vessel tortuosity in 27% of children [35].
Differences between genders have also been previously
noted, with vessel tortuosity described less frequently in
heterozygous female versus hemizygous male patients with
Fabry disease [17, 18, 30, 36, 37]. In the present analysis,
tortuous retinal or conjunctival vessels were seen in 49/229
children, which suggests that increased vessel tortuosity
could be an early, specific sign of Fabry disease. Allen et al
described the coexistence of symptoms of systemic
autonomic neuropathy with retinal vascular changes and
suggested a common pathogenesis [35]. The involvement
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tributory factor for vessel alterations that can be noted even
in childhood.
Future studies concerning the paediatric Fabry patient
population could use the age-specific FOS Paediatric
Health and Pain Questionnaire (FPHPQ), which has
recently been developed and validated [38].
As expected, children who were less symptomatic were
not generally receiving ERT. We observed that ocular
findings have not generally been a trigger to initiate
ERT, given the high percentage of children with ocular
findings not on ERT. No definitive effect of ERT on eye
findings has been described to date [30, 35, 36].Limitations of FOS
As a large international registry, FOS encompasses data
from 118 clinics in 22 countries worldwide and this
includes retrospective findings from a large number of
eye care practitioners who likely have varying assessment
strategies. FOS is a registry for patient data collected in
real-world clinical settings; thus, this was not a con-
trolled trial specifically designed to assess all parameters
reported here and there were no planned scheduled
assessments with all data evaluated, so only part of the
information might be collected at each patient visit.
Information regarding specific concurrent medications
that might induce similar eye findings was not available.
Furthermore, it lacks stringent inclusion and exclusion
criteria seen in clinical trial settings, and thus has the
potential for selection bias. In addition, the current
analyses were cross-sectional in nature and, ideally, a
controlled longitudinal study would be conducted to
confirm these results.Conclusions
Routine ocular examinations are important in the care
of children with Fabry disease. Because ocular signs can
occur without other objective clinical signs, they remain
a valuable tool in screening for Fabry disease. However,
the current analysis also supports the use of ocular signs
(together with other signs such as angiokeratoma and
further objective clinical features such as microalbumi-
nuria or left ventricular hypertrophy) to identify patients
at risk for severe disease manifestations.
These data further emphasise, in a large cohort, the
importance of ocular findings for the assessment of
disease severity in children with Fabry disease. To fully
understand the importance of ocular signs as predictors of
disease severity, it would be necessary to evaluate further,
in a systematic and prospective manner, the occurrence of
ocular findings and their correlation with an efficient
scoring system suited for children with Fabry disease.Additional files
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